Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 9:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HSP Clear all
Completed Phase 3 Interventional

Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma

NCT00039000
View directory record Official record
Conditions
Malignant Melanoma
Interventions
HSPPC-96 or Oncophage
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Berkeley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Sep 6, 2026, 9:27 PM EDT
Completed Phase 2Phase 3 Interventional

A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma

NCT00514371
View directory record Official record
Conditions
Multiple Myeloma
Interventions
tanespimycin, Bortezomib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
11
States / cities
Berkeley, California • San Francisco, California • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2015 · Synced Sep 6, 2026, 9:27 PM EDT
Terminated Phase 1 Interventional Results available

A Study of DS-2248 in Participants With Advanced Solid Tumors

NCT01288430
View directory record Official record
Conditions
Solid Tumors, Non-small Cell Lung Carcinoma
Interventions
DS-2248
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
9
States / cities
Duarte, California • Loma Linda, California • Orange, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Sep 6, 2026, 9:27 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer

NCT00003025
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
vitespen
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Sep 6, 2026, 9:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

NCT01259089
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Non-small Cell Lung Cancer
Interventions
erlotinib hydrochloride, Hsp90 inhibitor AUY922, laboratory biomarker analysis, needle biopsy, mutation analysis, pharmacological study
Drug · Other · Procedure + 1 more
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Sep 6, 2026, 9:27 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

NCT00054041
View directory record Official record
Conditions
Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 3, Human Papilloma Virus Infection
Interventions
HspE7, therapeutic conventional surgery, laboratory biomarker analysis
Biological · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
17 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Sep 6, 2026, 9:27 PM EDT
Terminated Phase 2 Interventional

A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma

NCT00627419
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
IPI-504
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
17
States / cities
Tuscon, Arizona • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2012 · Synced Sep 6, 2026, 9:27 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma

NCT02452281
View directory record Official record
Conditions
Melanoma
Interventions
ipilimumab, HSPPC-96
Drug
Lead sponsor
Rabih Said
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2016 · Synced Sep 6, 2026, 9:27 PM EDT
Not listed Phase 2 Interventional

SGN-00101 in Treating Patients With Cervical Intraepithelial Neoplasia

NCT00060099
View directory record Official record
Conditions
Precancerous Condition
Interventions
HspE7
Biological
Lead sponsor
Dana-Farber/Brigham and Women's Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Sep 6, 2026, 9:27 PM EDT
Completed Phase 3 Interventional

A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse

NCT00546780
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Tanespimycin, Bortezomib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
18
States / cities
Bakersfield, California • La Jolla, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Sep 6, 2026, 9:27 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer

NCT00627627
View directory record Official record
Conditions
Breast Cancer
Interventions
IPI-504
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Boca Raton, Florida • Lake Worth, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2010 · Synced Sep 6, 2026, 9:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma

NCT00293423
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
HSPPC-96, Standard Surgical Resection
Biological · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
3
States / cities
San Francisco, California • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 6, 2026, 9:27 PM EDT
Completed Phase 2 Interventional

A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma

NCT00081809
View directory record Official record
Conditions
Lymphoma, Follicular, Lymphoma, Small Lymphocytic
Interventions
autologous human tumor-derived HSPPC-96
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 6, 2026, 9:27 PM EDT
Terminated No phase listed Observational

Study of Disease Progression in Adults With Inherited Forms of Spastic Paraplegia

NCT05008874
View directory record Official record
Conditions
AMN, AMN Gene Mutation, X-ALD
Interventions
Natural History Observation
Other
Lead sponsor
SwanBio Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Stanford, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 6, 2026, 9:27 PM EDT
Terminated Phase 2 Interventional Results available

Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

NCT01814813
View directory record Official record
Conditions
Recurrent Glioblastoma, Recurrent Adult Brain Tumor, Gliosarcoma
Interventions
HSPPC-96, bevacizumab
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
417
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Little Rock, Arkansas + 268 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Sep 6, 2026, 9:27 PM EDT
Completed Phase 1 Interventional

Study Using Vaccination With Heat Shock Protein 70 (HSP70) for the Treatment of CML in Chronic Phase

NCT00027144
View directory record Official record
Conditions
Leukemia,Myeloid, Chronic, Leukemia,Myeloid,Philadelphia-Positive
Interventions
Heat Shock Protein 70 HSP70
Biological
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 6, 2026, 9:27 PM EDT
Completed Phase 2 Interventional Results available

STA-9090(Ganetespib) in Metastatic Ocular Melanoma

NCT01200238
View directory record Official record
Conditions
Ocular Melanoma
Interventions
STA-9090
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 6, 2026, 9:27 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)

NCT05394064
View directory record Official record
Conditions
AMN, AMN Gene Mutation, X-ALD
Interventions
SBT101 Treatment
Genetic
Lead sponsor
SwanBio Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 6, 2026, 9:27 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia

NCT04712812
View directory record Official record
Conditions
Hereditary Spastic Paraplegia, SPG47, SPG50, SPG51, SPG52, AP4-related Hereditary Spastic Paraplegia, Early Onset Hereditary Spastic Paraplegia, SPG4, SPG3A, SPG15, SPG11
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 30 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 6, 2026, 9:27 PM EDT
Completed Phase 1 Interventional

Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

NCT01294826
View directory record Official record
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Interventions
AUY922, Cetuximab
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 6, 2026, 9:27 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Phenotype, Genotype and Biomarkers 2

NCT04875416
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Hereditary Spastic Paraplegia, Primary Lateral Sclerosis, Progressive Muscular Atrophy, Frontotemporal Dementia
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
7 Years and older
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
3
States / cities
Miami, Florida • Kansas City, Kansas • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 6, 2026, 9:27 PM EDT
Completed Phase 1 Interventional

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

NCT02060253
View directory record Official record
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
ganetespib, paclitaxel, trastuzumab, pertuzumab
Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 6, 2026, 9:27 PM EDT
Terminated Phase 2 Interventional Results available

STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma

NCT01551693
View directory record Official record
Conditions
Melanoma
Interventions
STA-9090
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 6, 2026, 9:27 PM EDT
Terminated Phase 1Phase 2 Interventional

Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70

NCT00027131
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Heat Shock Protein 70-peptide complexes (HSP70)
Biological
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 7, 2008 · Synced Sep 6, 2026, 9:27 PM EDT